The efficacy and safety of regorafenib/fruquintinib combined with PD-1/PD-L1 for metastatic colorectal cancer: a meta-analysis based on single-arm studies

ObjectiveThe efficacy of regorafenib or fruquintinib in combination with PD-1/PD-L1 inhibitors for metastatic colorectal cancer (mCRC) treatment has not been elucidated. This study aims to systematically evaluate the efficacy and safety of this combination therapy.MethodsPubMed, Embase, Cochrane Lib...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Fan Yang, Ying Mao, Hanyu Huang, Wen Luo, Li Liu, Wenzhi Chen
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Frontiers Media S.A. 2025-05-01
Colecção:	Frontiers in Immunology
Assuntos:	metastatic colorectal cancer regorafenib fruquintinib PD-1/PD-L1 inhibitors meta-analysis
Acesso em linha:	https://www.frontiersin.org/articles/10.3389/fimmu.2025.1579293/full
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!